Compounds > oleanolic acid
Page last updated: 2024-08-21

oleanolic acid and Multiple Myeloma

oleanolic acid has been researched along with Multiple Myeloma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
John, T; Ma, H; Park, J; Rayalam, S; Rogers, LJ; Tucker, M; Wang, X; Wu, Y1
Anderson, K; Ikeda, T; Kimura, F; Kufe, D; Motoyoshi, K; Nakata, Y; Sato, K; Sporn, M1
Anderson, KC; Catley, L; Chauhan, D; Gribble, GW; Hideshima, T; Honda, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R; Shringarpure, R; Sporn, MB; Suh, N; Tai, YT1
Gribble, GW; Honda, T; Letterio, JJ; Liby, K; Risingsong, R; Royce, DB; Sporn, MB; Voong, N; Williams, CR1

Other Studies

4 other study(ies) available for oleanolic acid and Multiple Myeloma

ArticleYear
Growth inhibition and apoptosis of human multiple myeloma cells induced by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid derivatives.
    Anti-cancer drugs, 2020, Volume: 31, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Multiple Myeloma; Oleanolic Acid; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment

2020
Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:1

    Topics: Antioxidants; Apoptosis; Bone Marrow Cells; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Glutathione; Humans; Imidazoles; Intracellular Membranes; Intracellular Signaling Peptides and Proteins; Membrane Potentials; Mitochondria; Multiple Myeloma; Oleanolic Acid; Oxidation-Reduction; Reactive Oxygen Species

2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
    Blood, 2004, Apr-15, Volume: 103, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, bcl-2; Humans; Imidazoles; Insulin-Like Growth Factor I; Interleukin-6; Lymphocytes; Membrane Potentials; Mitochondria; Multiple Myeloma; Mutation; NF-kappa B; Oleanolic Acid; Protease Inhibitors; Pyrazines; Recombinant Proteins; Transfection

2004
The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-15, Volume: 12, Issue:14 Pt 1

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunoblotting; Interleukin-6; Lung Neoplasms; Multiple Myeloma; Oleanolic Acid; Phosphorylation; Signal Transduction; STAT Transcription Factors; STAT5 Transcription Factor; Time Factors; Transcription, Genetic

2006